Two studies have identified military service as a risk factor for certain urologic disorders in presentations made at the AUA annual meeting in Atlanta.
Two studies have identified military service as a risk factor for certain urologic disorders in presentations made at the AUA annual meeting in Atlanta.
In the first study, researchers from the University of Alabama, Birmingham and Emory University, Atlanta found that prior military exposure is a risk factor for moderate/severe urinary incontinence among U.S. men, even after consideration of other known risk factors. The authors reviewed survey data from 5,297 men 20 years of age and older to establish the study population. The dataset was stratified into three age groups (70 years of age), and a multivariable logistic regression model was reassessed for each population.
Results indicated that men with military exposure had a higher rate of any urinary incontinence (18.8% vs. 10.4%, pp
A separate study from the University of California, San Francisco found that lower urinary tract symptoms are prevalent among Iraq and Afghanistan war veterans enrolled in Veteran Affairs health care who have received posttraumatic stress disorder (PTSD) diagnoses.
The retrospective study analyzed data from Iraq and Afghanistan veterans following the end of military service. The prevalence of PTSD and LUTS during the study period was 28.5% and 1.6%, respectively. Male veterans with PTSD compared with those without PTSD were more likely to suffer from LUTS (2.9% vs. 1.1%, p
"Both studies show a connection between military service and the development of urinary symptoms," said Christopher Amling, MD, of the Oregon Health Sciences University, Portland, who moderated an AUA press briefing during which these studies were discussed. "We hope that results will help us glean further insight into the potential long-term health effects associated with service in the armed forces, including how to prevent them."
Go back to this issue of Urology Times eNews.
Related Content
Sling procedures for SUI increase fourfold but do not replace alternatives
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.